Antibe Therapeutics (STU:4B70) Cash Flow for Dividends: €0.00 Mil (TTM As of Dec. 2023)


STU:4B70 Antibe Therapeutics Inc STU:4B70
10 GF Score
Price €2.44
View Full Analysis

What is Antibe Therapeutics Cash Flow for Dividends?

Antibe Therapeutics STU:4B70 10 Cash Flow for Dividends is €0.00 Mil as of Dec. 2023. GuruFocus rates STU:4B70 with a GF Score™ of 10/100.

Antibe Therapeutics's cash flow for dividends for the three months ended in Dec. 2023 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Antibe Therapeutics Cash Flow for Dividends Related Terms

Antibe Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Antibe Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Antibe Therapeutics Cash Flow for Dividends Chart

Antibe Therapeutics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Antibe Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:4B70
10GF Score
Antibe Therapeutics Inc STU:4B70
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Antibe Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Antibe Therapeutics (STU:4B70) has a Cash Flow for Dividends of €0.00 Mil as of Dec. 2023. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Antibe Therapeutics and its competitors.
Is Antibe Therapeutics' Cash Flow for Dividends too high?
Antibe Therapeutics' current Cash Flow for Dividends is €0.00 Mil. Overall, Antibe Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Antibe Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
Antibe Therapeutics' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Antibe Therapeutics and its competitors. Antibe Therapeutics's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibe Therapeutics stock overvalued right now?
Antibe Therapeutics (STU:4B70) has a current Cash Flow for Dividends of €0.00 Mil. The current Cash Flow for Dividends is €0.00 Mil. Antibe Therapeutics' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Antibe Therapeutics (STU:4B70), the current Cash Flow for Dividends is €0.00 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Antibe Therapeutics Business Description

Address 15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2
Antibe Therapeutics Inc is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide (H2S) platform to develop next-generation therapies to address inflammation arising from a wide range of medical conditions. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Antibe's drug, otenaproxesul, is in development for the treatment of acute and chronic pain. The company's second pipeline drug is a GI-sparing alternative to ketoprofen. The company's next target is inflammatory bowel disease (IBD), a condition long in need of safer, more effective therapies.
10GF Score

Get the complete analysis for STU:4B70

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price